Methotrexate Drugs Market Size & Share, by Dosage Form (>10 mg, >15 mg/ml, 17.5 mg/ml - 25 mg/ml); Disease Type (Cancer, Autoimmune Diseases, Ectopic Pregnancy); Drug Type (Branded, Generics); Route of Administration (Injectable, Oral); End-user (Hospitals, Specialty Clinics, Home Healthcare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 2738
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Global Methotrexate Drug Market TOC

 

  1. Market Definition
    1. Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. Suppliers/Distributors
      3. End-Users
    3. Secondary Research
    4. Market Size Estimation
  4. Analyst Review
  5. Executive Summary – Global Methotrexate Drug Market
  6. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Market Trends
    4. Opportunities
  7. Regulatory and Standards Landscape
    1. FDA
    2. WHO
    3. Others
  8. Industry Risk Analysis
  9. World Economic Outlook: Challenges for Global Recovery and its Impact on Global Methotrexate Drug Market
  10. Impact of COVID-19 on the Global Methotrexate Drug Market
  11. Epidemiology Analysis of Cancer and Rheumatoid Arthritis
  12. End-user analysis
  13. Industry Supply Chain Analysis
  14. Competitive Landscape
    1. Company Market Share Analysis
    2. Company Profiles
      1. Pfizer Inc.
      2. Azurity Pharmaceuticals, Inc.
      3. Cumberland Pharmaceuticals Inc.
      4. Teva Pharmaceuticals USA, Inc.
      5. Amneal Pharmaceuticals LLC
      6. Sun Pharmaceutical Industries Ltd.
      7. Aurobindo Pharma Limited,
      8. Sandoz Inc
      9. Hikma Pharmaceuticals PLC
      10. Eisai Co., Ltd.
      11. Other prominent players
  15. Global Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type  
        1. >10 mg, 2023-2036F (USD Million)
        2. >15 mg/ml, 2023-2036F (USD Million)
        3. 17.5 mg/ml – 25 mg/ml, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      2. By Disease Type
        1. Cancer, 2023-2036F (USD Million)
          1. Breast Cancer, 2023-2036F (USD Million)
          2. Leukemia, 2023-2036F (USD Million)
          3. Lung Cancer, 2023-2036F (USD Million)
          4. Lymphoma, 2023-2036F (USD Million)
          5. Gestational Trophoblastic Disease, 2023-2036F (USD Million)
          6. Osteosarcoma, 2023-2036F (USD Million)
        2. Autoimmune Diseases, 2023-2036F (USD Million)
          1. Psoriasis, 2023-2036F (USD Million)
          2. Rheumatoid Arthritis, 2023-2036F (USD Million)
          3. Crohn's Disease, 2023-2036F (USD Million)
          4. Others, 2023-2036F (USD Million)
        3. Ectopic Pregnancy, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      3. By Drug Type
        1. Branded, 2023-2036F (USD Million)
        2. Generics, 2023-2036F (USD Million)
      4. By Route Of Administration
        1. Injectable, 2023-2036F (USD Million)
        2. Oral, 2023-2036F (USD Million)
      5. By End User
        1. Hospitals, 2023-2036F (USD Million)
        2. Specialty Clinics, 2023-2036F (USD Million)
        3. Home Healthcare, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      6. By Region
        1. North America, 2023-2036F (USD Million)
        2. Europe, 2023-2036F (USD Million)
        3. Asia Pacific, 2023-2036F (USD Million))
        4. Latin America, 2023-2036F (USD Million)
        5. Middle East & Africa, 2023-2036F (USD Million)
  16. North America Methotrexate Drug Market 2023-2036
    1.  Market Overview
    2. By Value (USD Million)
      1. By Type 
        1. >10 mg, 2023-2036F (USD Million)
        2. >15 mg/ml, 2023-2036F (USD Million)
        3. 17.5 mg/ml – 25 mg/ml, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      2. By Disease Type
        1. Cancer, 2023-2036F (USD Million)
          1. Breast Cancer, 2023-2036F (USD Million)
          2. Leukemia, 2023-2036F (USD Million)
          3. Lung Cancer, 2023-2036F (USD Million)
          4. Lymphoma, 2023-2036F (USD Million)
          5. Gestational Trophoblastic Disease, 2023-2036F (USD Million)
          6. Osteosarcoma, 2023-2036F (USD Million)
        2. Autoimmune Diseases, 2023-2036F (USD Million)
          1. Psoriasis, 2023-2036F (USD Million)
          2. Rheumatoid Arthritis, 2023-2036F (USD Million)
          3. Crohn's Disease, 2023-2036F (USD Million)
          4. Others, 2023-2036F (USD Million)
        3. Ectopic Pregnancy, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      3. By Drug Type
        1. Branded, 2023-2036F (USD Million)
        2. Generics, 2023-2036F (USD Million)
      4. By Route Of Administration
        1. Injectable, 2023-2036F (USD Million)
        2. Oral, 2023-2036F (USD Million)
      5. By End User
        1. Hospitals, 2023-2036F (USD Million)
        2. Specialty Clinics, 2023-2036F (USD Million)
        3. Home Healthcare, 2023-2036F (USD Million)
        4. Others, 2023-2036F (USD Million)
      6. By Country
        1. United States, 2023-2036F (USD Million)
        2. Canada, 2023-2036F (USD Million)
  17. Europe Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type  
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. United Kingdom, 2023-2036F (USD Million)
        2. Germany, 2023-2036F (USD Million)
        3. France, 2023-2036F (USD Million)
        4. Italy, 2023-2036F (USD Million)
        5. Spain, 2023-2036F (USD Million)
        6. Russia, 2023-2036F (USD Million)
        7. Netherlands, 2023-2036F (USD Million)
        8. Rest of Europe, 2023-2036F (USD Million)
  18. Asia Pacific Methotrexate Drug Market 2023-2036
    1.  Market Overview
    2. By Value (USD Million)
      1. By Type  
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. China, 2023-2036F (USD Million)
        2. India, 2023-2036F (USD Million)
        3. Japan, 2023-2036F (USD Million)
        4. South Korea, 2023-2036F (USD Million)
        5. Singapore, 2023-2036F (USD Million)
        6. Australia, 2023-2036F (USD Million)
        7. Rest of Asia Pacific, 2023-2036F (USD Million)
  19. Latin America Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type 
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. Brazil, 2023-2036F (USD Million)
        2. Mexico, 2023-2036F (USD Million)
        3. Argentina, 2023-2036F (USD Million)
        4. Rest of Latin America, 2023-2036F (USD Million)
  20. Middle East & Africa Methotrexate Drug Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
      1. By Type 
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. Israel, 2023-2036F (USD Million)
        2. GCC, 2023-2036F (USD Million)
        3. South Africa, 2023-2036F (USD Million)
        4. Rest of Middle East & Africa, 2023-2036F (USD Million)

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Methotrexate Drugs Market size was valued at USD 584.09 million in 2024 and is set to exceed USD 846.99 million by 2037, registering over 2.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of methotrexate drugs is estimated at USD 597.64 million.

The demand for methotrexate drugs is owing to the increasing use of the drugs for various inflammatory diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, and lupus. About 60% of people with rheumatoid arthritis are presently taking methotrexate, which is the recommended first-line treatment for rheumatoid arthritis, according to the American College of Rheumatology.

Moreover, the rising prevalence of autoimmune diseases is driving the demand for methotrexate drugs across the globe. As manufacturers are focusing on innovating new drugs in order to reduce the challenges faced by patients.


Get more information on this report: Request Free Sample PDF

Methotrexate Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Cancer – Methotrexate is commonly used in chemotherapy. It's a treatment for several different types of cancer. Although Methotrexate is not a first-line drug against breast cancer, it might be valuable in fighting the disease due to which the methotrexate drugs market rapidly expanding. According to the World Health Organization (WHO), cancer was the top cause of death globally in 2020, accounting for close to more than 10 million deaths, or about one in every six. The most prevalent types are breast, lung, colon, rectum, and prostate cancers. The second most significant cause of death for women after lung cancer is breast cancer, the most recurring invasive cancer in females.
  • Need for Cost-Effective Medicines- Methotrexate has been on the market for several decades, making it a relatively affordable option compared to newer, more expensive drugs. Its cost-effectiveness has made it a preferred choice for healthcare providers and patients.
  • Increasing Number of Methotrexate Drugs Approvals – The rising number of drug approval is expected to increase the methotrexate drugs market growth. For example, U.S. specialty pharmaceutical company Cumberland Pharmaceuticals Inc. announced the launch of her RediTrex injection in November 2020. RediTrex is a new prefilled syringe specifically designed for precise dosing for subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis and is easy to use. Besides, in July 2022, The US Food and Drug Administration approved use of methotrexate to lower serum uric acid levels (sUA) in patients with chronic gout.

Challenges

  • Obstruction of Approval of Methotrexate Injection - Due to its drawbacks such as the lengthy development process and stringent regulations, the methotrexate drugs market is facing certain limitations across the world. As methotrexate injection may cause a serious, life-threatening reaction that may occur while or shortly after one receives this medication. Moreover, for individualized prediction of response to methotrexate treatment in patients with RA, clinically useful tools are lacking, which is also a key threat to the market.
  • Lack of Awareness and High Cost of Rheumatoid Arthritis Drugs
  • Side Effects Caused by the Drug

Methotrexate Drugs Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

2.9%

Base Year Market Size (2024)

USD 584.09 million

Forecast Year Market Size (2037)

USD 846.99 million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Brazil, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, South Korea, Singapore, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, Netherlands, Rest of Europe)
  • Middle East and Africa (Israel, GCC, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Methotrexate Drugs Segmentation

Disease Type (Cancer, Autoimmune Diseases, Ectopic Pregnancy)

The cancer segment in the methotrexate drugs market is expected to grow at a CAGR of 3.2% during the forecast period. Methotrexate drugs slows down the growth of cancer cells. The growth of the segment is due to the rising incidence rates of various types of cancers across the globe. For instance, according to the National Cancer Institute, Prostate, lung, and colorectal cancers account for an estimated 43% of all cancers diagnosed in men in 2020. For women, the three most common cancers are colorectal, breast, and lung which accounted for an estimated 50% of all new cancer diagnoses in women in 2020. In addition, higher usage of methotrexate in cancer treatment than in arthritis or psoriasis is also a major factor catering to the segment’s growth in the market. It is the initial treatment administered to cancer patients and is also used in combination therapy. In Japan, methotrexate is administered as the first-line treatment for cancer.

End-User (Hospitals, Specialty Clinics, Home Healthcare)

Methotrexate drugs market from the hospital segment is expected to garner a significant share by 2037, due to the increasing influx of patients with target diseases. Methotrexate is a kind of chemotherapy, and it is a treatment for a variety of cancers. According to the National Library of Medicine, in the United States, an estimated 60,000 cancer patients with cancer are hospitalized each year for chemotherapy. As the number of patients seeking treatment at hospitals continues to rise, the segment is further expected to grow with the highest CAGR of 3.3% during the forecast period. Besides, specialty clinics are expected to grow at a significant growth rate.

Our in-depth analysis of the global methotrexate drugs market includes the following segments:

     Dosage Form

  • >10 mg
  • >15 mg./ml
  • 17.5 mg/ml – 25 mg/ml

     Drug Type

  • Branded
  • Generics

     Disease Type

  • Cancer
  • Autoimmune Diseases
  • Ectopic Pregnancy

     Route of Administration

  • Injectable
  • Oral

     End-User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Methotrexate Drugs Industry- Regional Synopsis

North American Market Forecast

The North America methotrexate drugs market is projected to hold a significant market share of 41% by the end of 2037. The demand for methotrexate drugs is propelling in the region due to its high adoption of innovative technologies, and higher healthcare expenditures. In addition, the immediate availability of methotrexate pharmacotherapy, growing research and development linked to methotrexate drugs, multiple cancer survivor campaigns, high rates of psoriasis and arthritis, and the accessibility of reimbursement policies are also expected to contribute to regional growth. Also, the rising number of products and drugs that have been approved by the authorities. For example, U.S. specialty pharmaceutical company Cumberland Pharmaceuticals Inc. announced the launch of her RediTrex injection in November 2020. RediTrex is a new prefilled syringe specifically designed for ease of Use and precise dosing for subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis.

APAC Market Statistics

The Asia-Pacific methotrexate drugs market is predicted to have notable growth during the forecasted timeframe. The demand for methotrexate drugs in the region is majorly due to the increasing awareness of different medical modalities. Moreover, there are surging number of female populations requiring a medical abortion in the Asia Pacific region.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Methotrexate Drugs Market

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Azurity Pharmaceuticals, Inc.
    • Cumberland Pharmaceuticals Inc.
    • Teva Pharmaceuticals USA, Inc.
    • Amneal Pharmaceuticals LLC
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma Limited,
    • Sandoz Inc
    • Hikma Pharmaceuticals PLC
    • Eisai Co., Ltd.

In the News

  • Eisai Co., Ltd and nippon medac Co., Ltd. announced a manufacturing and marketing approval of Metoject Subcutaneous Injection (Methotrexate) from the Japanese Ministry of Health, Labour and Welfare for the treatment of rheumatoid arthritis.
  • Cumberland Pharmaceuticals Inc. announced the launch of RediTrex (methotrexate) injection which is designed for dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.

     

Author Credits:  Radhika Pawar


  • Report ID: 2738
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of methotrexate drugs is estimated at USD 597.64 million.

The methotrexate drugs market size was valued at USD 584.09 million in 2024 and is set to exceed USD 846.99 million by 2037, registering over 2.9% CAGR during the forecast period i.e., between 2025-2037. The surge in the prevalence of rheumatoid arthritis and the increasing prevalence of cancer will drive the market growth.

North America industry is set to hold largest revenue share of 41% by 2037, due to rising demand for methotrexate drugs in the region.

The major players in the market include Pfizer Inc., Azurity Pharmaceuticals, Inc., Cumberland Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Sandoz Inc, Hikma Pharmaceuticals PLC, Eisai Co., Ltd.
Methotrexate Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample